The Centers for Medicare & Medicaid Services yesterday approved a Medicaid state plan amendment allowing Washington state to negotiate supplemental rebate agreements with drug makers based on value. CMS has approved similar state plan amendments for Oklahoma, Michigan and Colorado, but this is the first to focus on Hepatitis C drugs. Specifically, it allows the state to negotiate under a subscription model to pay a fixed annual amount to purchase an unrestricted supply of Hepatitis C drugs.

Related News Articles

Headline
Ashley Thompson, AHA senior vice president of public policy analysis and development, participated in a panel discussion during Modern Healthcare's Leadership…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…
Headline
A bipartisan House letter by Reps. Dan Crenshaw, R-Texas, Yvette D. Clarke, D-N.Y., Gus M. Bilirakis, R-Fla., and Diana DeGette, D-Colo., urged House…
Headline
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
The AHA Sept. 15 urged Aetna to rescind its recently announced “level of severity inpatient payment” policy, saying that it “could erode the transparency…
Headline
The AHA detailed its key health care priorities for the remainder of the year in comments to House and Senate majority and minority leaders Sept. 15. The AHA…